Inflammatory markers and aortic aneurysms | IJGM

Introduction

Thoracic aortic aneurysms (TAA) have an estimated incidence of at least 5–10 per 100,000 person-years.¹ The cause, natural history, and treatment vary depending on the location of the TAA. Aortic root or ascending aortic aneurysms are most common types (approximately 60%), followed by aneurysms of the descending aorta (approximately 35%) and aortic arch (2 There are many causes of aneurysm, like heritable disorders, genetic disorders, and degenerative, mechanical, and infectious diseases. Both Abdominal and ascending aortic aneurysms share the same risk factors, including male gender, smoking, age, history of myocardial infarction, hypertension, low high-density lipoprotein (HDL) cholesterol concentration, and a high concentration of total serum cholesterol.^3,4 Besides these well-known risk factors, primary hyperaldosteronism is an uncommon risk factor for acute aortic dissection.⁵ The importance of ascending aortic aneurysms resides in their capacity to induce life-threatening complications and the requirement for efficient management strategies. Ascending aortic aneurysms have a high likelihood of causing serious health problems and death. If not properly treated, there is a risk of life-threatening complications such as rupture and dissection.⁶ In a recent study, 27% of patients with AAA also presented with an ascending AA, most of whom were women, and the elderly.⁷ These coexistences of abdominal aneurysm and ascending aneurysm bring to our mind the possibility of sharing the same etymology. The inflammation in the etymology of AAA has been demonstrated in many studies, but it is still not well known if the inflammation has a role in the development of aneurysms in the ascending aorta. The coexistence of inflammatory cells with markers of apoptotic vascular cell death in the media of ascending aortas with aneurysms and type A dissection raises the possibility that activated T cells and Macrophages may contribute to the elimination of smooth muscle cells and the degradation of the matrix associated with thoracic aortic aneurysms and dissections.⁸ Several studies showed the role of inflammation and the relationship between CRP and AAA.^9,10 Also, it has been shown that CRP is specifically deposited on the interface between the atheroma and the damaged aortic wall in AAA, and in the same study, there was a high level of CRP in patients with ascending Aortic aneurysm.¹¹ Since aortic aneurysms are mainly asymptomatic during their clinical course until their complications—which may be lethal—serum biomarkers for their early diagnosis are a necessity.

C-reactive protein (CRP) and high-sensitivity CRP C-reactive protein (hs-CRP) serves as indicators of widespread inflammation and have been linked to a range of health conditions, such as cardiovascular diseases. Research has demonstrated a correlation between increased levels of hs-CRP and vascular remodeling as well as the rupture of coronary atherosclerotic plaques.¹² This suggests that hs-CRP plays a role in the advancement of atherosclerotic disease. Studies have shown that elevated levels of plasma D-dimer and hypersensitive C-reactive protein (hs-CRP) are indicative of aortic dissection and aneurysm.¹³ The aim of this study was to measure hs-CRP levels in people with isolated ascending aortic aneurysm and compare them with control subjects to assess whether this marker can be of value in this group of patients.

Methods

Study Population

We enrolled a total of 135 consecutive patients diagnosed with ascending aortic aneurysm (Asc AA) with a mean age of 57.1 ± 7.3 years, of which 76 (80%) were men. Additionally, 40 control subjects with a mean age of 54.2 ± 6.8 years, including 8 (20%) men, were recruited from the outpatient cardiology department at Ordu State Hospital. All patients underwent an echocardiography examination conducted by two independent cardiologists. The ascending aorta was assessed in transthoracic parasternal long-axis view. Patients with a diameter above 40 mm were included in the patient group (95 patients), while those with a diameter below this threshold were included in the control group (40 patients). Full blood count and biochemical tests were performed on the day of the outpatient visit, and demographic patient characteristics were obtained through interviews, including gender, age, smoking history, hypertension, cardiovascular medication (including statins), family history, presence of diabetes mellitus (use of insulin or oral antidiabetic drugs), and coronary artery disease status.

CT Imaging Techniques

All patients underwent computed tomography (CT) imaging. The diameter of the ascending aorta was independently determined from the echocardiography results by a radiologist. For each examination, the radiologist generated double-oblique short-axis views through the proximal aorta using an independent imaging workstation (Vital Images workstations, Vitrea 6.0.1 3D analysis software, Minnetonka, MN). Measurements were manually obtained from these images to determine the largest diameter at the annulus, sinuses (cusp to cusp), Sino tubular junction, and mid-ascending aorta.

Determination of Serum CRP

Venous blood samples were drawn on the day of the echocardiography examination and immediately centrifuged for 10 minutes at 1200 rpm and at 4°C. Serum samples were stored at −20°C until analysis. The highly sensitive (hs-CRP) IMMULITE CRP method (Diagnostic Product Corporation) with a detection limit of 0.10 mg/L was used to measure the levels of C-reactive protein (CRP). Patients were excluded if there was evidence of acute illness or infection, active inflammatory conditions, malignancy, or corticosteroid use.

Exclusion Criteria

Patients with any valve diseases, such as bicuspid valve, aortic valve regurgitation, and aortic valve stenosis, were excluded from the study. Only patients with isolated ascending aorta aneurysms were included.

Results

The baseline characteristics of the AA+ and AA- patient groups were summarized in Table 1. A total of 135 patients were included in the analysis, comprising 95 (70.3%) AA+ patients with a mean age of 57.0±7.3 years, of whom 76 (80%) were men, and 40 (29.7%) control subjects with a mean age of 54.2±6.8 years, of whom 8 (20%) were men. No statistically significant differences were observed between the groups in terms of antihypertensive drug usage, β-blocker usage, hyperlipidemia, coronary artery disease, hypertension, or diabetes mellitus. However, several parameters differed significantly between the AA+ and control groups. Some of the things that were more common in AA+ patients than in the control group were gender (p=0.006), age (p=0.04), creatinine levels (0.86±0.13 vs 0.81±0.12; p=0.043), hs-CRP levels (4.0±2.4 vs 2.2±1.8; pTable 2). Hs-CRP (OR 1.527, 95% CI 1.117 to 2.086, p=0.008), MPV (OR 0.381, 95% CI 0.250 to 0.582, pTable 3). Furthermore, in ROC analysis, a cutoff value of 2.15 for hs-CRP demonstrated a sensitivity of 68% and a specificity of 60% for predicting AA patients (AUC: 0.723, pFigure 1). These findings underscore the importance of hs-CRP, MPV, and platelet count as potential biomarkers for identifying AA patients. Correlation analyses were performed. The findings showed that hs-CRP levels were significantly positively related to the presence of AA (r = 0.45, p